Replies to post #92330 on Avid Bioservices Inc (CDMO)

[RRdog]

FTM,

Sounds like we are agreed on a slight change for the 2nd line NSCLC Phase III trial from split dosage to maximum dosage to optimize results based on the Phase II results.

Best
RRdog

[immunidose]

Free,

1st line NSCLC Bavituximab results will carry weight on determining P111 dosage protocols. Anyone doubt that we see first-line results + BP announced simultaneously?

Well, this Ihub rookie is out of allotted post.

Thanks,
JBradley